Immutep (IMMP) Other Non-Current Liabilities (2012 - 2025)
Immutep's (IMMP) quarterly Other Non-Current Liabilities came in at $18640.8 in Q4 2025, down 99.71% YoY from $6.4 million in Q4 2024, and up 245.6% on a QoQ basis from $5393.7 in Q2 2025.
Immutep (IMMP) Other Non-Current Liabilities (2012 - 2025) Analysis & Trends
Immutep (IMMP) has 12 years of Other Non-Current Liabilities data on file, last reported at $18640.8 in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 99.71% year-over-year to $18640.8 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18640.8 (down 99.71% YoY) and the FY2025 annual result came in at $5393.7, down 99.93% from the prior year.
- Other Non-Current Liabilities grew to $18640.8 in Q4 2025, from $5393.7 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $8.3 million in Q4 2021 to a low of $5164.8 in Q2 2024.
- A 5-year average of $2.7 million and a median of $557551.4 in 2021 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities jumped 1077.83% — and 2025, when it tumbled 99.71%.
- Tracing IMMP's Other Non-Current Liabilities over 5 years: stood at $8.3 million in 2021, then slipped by 25.79% to $6.1 million in 2022, then dropped by 13.4% to $5.3 million in 2023, then climbed by 21.55% to $6.4 million in 2024, then plunged by 99.71% to $18640.8 in 2025.
- The last three Other Non-Current Liabilities figures came in at $18640.8 (Q4 2025), $5393.7 (Q2 2025), and $6.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Immutep | 56.46 Mn | -8.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18,640.84 |
| Jun 30, 2025 | 5,393.73 |
| Dec 31, 2024 | 6.45 Mn |
| Jun 30, 2024 | 5,164.77 |
| Dec 31, 2023 | 5.30 Mn |
| Jun 30, 2023 | 558,379.06 |
| Dec 31, 2022 | 6.12 Mn |
| Jun 30, 2022 | 94,472.93 |
| Dec 31, 2021 | 8.25 Mn |
| Jun 30, 2021 | 556,723.69 |
| Dec 31, 2020 | 700,563.70 |
| Jun 30, 2020 | 622,387.43 |
| Dec 31, 2019 | 10.20 Mn |
| Jun 30, 2019 | 11.32 Mn |
| Dec 31, 2018 | 10.55 Mn |
| Jun 30, 2018 | 2.23 Mn |
| Jun 30, 2017 | 4.34 Mn |
| Mar 31, 2017 | 4.23 Mn |
| Dec 31, 2016 | 5.18 Mn |
| Jun 30, 2016 | 3.75 Mn |